Adoptive immunotherapy with tumor-cytotoxic macrophages derived from recombinant human granulocyte-macrophage colony-stimulating factor (rhuGM-CSF) mobilized peripheral blood monocytes

Journal of Immunotherapy

Volumn 20, Issue 5, 1997, Pages 365-371

  Hennemann, B ^a   Rehm, A ^a   Kottke, A ^b   Meidenbauer, N ^a   Andreesen, R ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b Essex Pharma   (Germany)

Author keywords

Adoptive immunotherapy; Granulocyte macrophage colony stimulating factor; Interferon ; Monocytes macrophages

Indexed keywords

RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CYTOTOXICITY TEST; FEVER; HUMAN; LEUKAPHERESIS; LEUKOCYTE COUNT; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MONOCYTE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0031467930     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199709000-00005     Document Type: Article

References (30)

1. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lympho kine-activated killer cell phenomenon. J Exp Med 1982;155:1823-41.
2. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986;233:1318-21.
3. Fidler IJ. Inhibition of pulmonary metastasis by intravenous injection of specifically activated macrophages. Cancer Res 1974; 34: 1074-8.
4. Chakraborty NG, Okino T, Stabach P, et al. Adoptive transfer of activated human autologous macrophages results in regression of transplanted human melanoma cells in scid mice. In Vivo 1991; 5: 609-14.
5. Bartholeyns J, Lombard Y, Poindron P. Immunotherapy of murine sarcoma by adoptive transfer of resident peritoneal macrophages proliferating in culture. Anticancer Res 1988;8:145-52.
6. Chokri M, Freudenberg M, Galanos C, Poindron P, Bartholeyns J. Antitumoral effects of lipopolysaccharides, tumor necrosis factor, interferon and activated macrophages: synergism and tissue distribution. Anticancer Res 1989;9:1185-90.
7. Andreesen R, Picht J, Löhr GW. Primary cultures of human blood borne macrophages grown on hydrophobic Teflon membranes. J Immunol Methods 1983;56:295-304.
8. Andreesen R, Bross KJ, Osterholz J, Emrich F. Human macrophage maturation and heterogeneity: analysis with a newly generated set of monoclonal antibodies to differentiation antigens. Blood 1986;67:1257-64.
9. Andreesen R, Osterholz J, Bross KJ, Schulz A, Löhr GW. Cytotoxic effector cell function at different stages of human monocyte macrophage maturation. Cancer Res 1983;43:5931-6.
10. Andreesen R, Brugger W, Gadd S, Löhr GW, Atkins RC. Activation of human monocyte-derived macrophages cultured on Teflon: response to interferon-gamma during terminal maturation in vitro. Immunobiology 1988;177:186-98.
11. Stevenson HC, Lacarna LV, Sugarbaker PH. Ex vivo activation of killer monocytes (AKM) and their application to the treatment of human cancer. J Clin Apheresis 1988;4:118-21.
12. Andreesen R, Scheibenbogen C, Krause S, et al. Adoptive transfer of tumorcytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy. Cancer Res 1990;50:7450-6.
13. Brugger W, Scheibenbogen S, Krause S, Andreesen R. Large scale production of human tumorcytotoxic macrophages grown from blood monocytes for the use in adoptive immunotherapy trials. Cancer Detect Prevent 1991;15:407-12.
14. Faradji A, Bohbot A, Schmitt-Goguel M, et al. Phase I trial of intravenous infusion of ex-vivo-activated autologous blood derived macrophages in patients with non-small-cell lung cancer: toxicity and immunomodulatory effects. Cancer Immunol Immu nother 1991;33:319-26.
15. Lopez M, Fechtenbaum J, David B, et al. Adoptive immunotherapy with activated macrophages grown in vitro from blood monocytes in cancer patients: a pilot study. J Immunother 1992;11:209-17.
16. Hennemann B, Scheibenbogen C, Schiimichen C, Andreesen R. Intrahepatic adoptive immunotherapy with autologous tumorcytotoxic macrophages in patients with cancer. J Immunother 1995; 18: 19-27.
17. Andreesen R, Hennemann B. Adoptive immunotherapy with autologous macrophages: current status and future perspectives. Pathobiology 1991;59:259-63.
18. Broxmeyer HE, Cooper S, Williams DE, et al. Growth characteristics of marrow hematopoietic progenitor/precursor cells from patients on a phase I clinical trial with purified recombinant human granulocyte-macrophage colony stimulating factor. Exp Hematol 1988;16:594-602.
19. Hermann F, Schulz G, Lindemann A, et al. Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor. J Clin Oncol 1989;7:159-67.
20. Lieschke GJ, Maher D, Cebon J, et al. Effects of bacterial synthesized recombinant human granulocyte-macrophage colony stimulating factor in patients with advanced malignancy. Ann Intern Med 1989;110:357-64.
21. Frenck RW, Sarman G, Harper TE, et al. The ability of recombinant murine granulocyte-macrophage colony-stimulating factor (GM-CSF) to protect neonatal rats from septic death due to Staphylococcus aureus. J Infect Dis 1990;162:109-14.
22. Grabstein KH, Urdal DL, Tushinski RJ, et al. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor. Science 1986;232:506-8.
23. Braun DP, Sizipilou KP, Casey LC, Harris PE. The in vitro development of cytotoxicity in response to granulocyte-macrophage colony-stimulating factor or interferon-7 in the peripheral blood monocytes of patients with solid tumors: modulation by arachi donic acid metabolic inhibitors. Cancer Immunol Immunother 1990;32:55-61.
24. Masucci G, Wersäll P, Ragnhammar P. Mellstedt H. Granulocyte monocyte colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother 1989;29:288-92.
25. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J Immunol Methods 1983;65:55-63.
26. Steinman RM. Dendritic cells and immune based therapies. Exp Hematol 1996;24:859-62.
27. Wing JW, Magee DM, Whiteside TL, Kaplan SS, Shadduck RK. Recombinant human granulocyte macrophage colony stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor and interferon of cancer patients. Blood 1989; 73: 634-6.
28. Chachoua A, Oratz R, Hoogmoed X, et al. Monocyte activation following systemic administration of granulocyte-macrophage colony-stimulating factor. J Immunother 1994;15:217-24.
29. Wiltschke C, Krainer M, Wagner A, Linkesch W, Zielinski C. Influence of in vivo administration of GM-CSF and G-CSF on monocyte cytotoxicity. Exp Hematol 1995;23:402-6.
30. Ragnhammar P, Masucci G, Frodin JE, Hjelm AL, Mellstedt H. Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/ macrophage colony-stimulating factor. Cancer Immunol Immunother 1992;35:158-64.